Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs.

Virology Swine Research Unit, Agricultural Research Service, Ames, Iowa.
Archives of Virology (Impact Factor: 2.28). 09/1994; 134(3-4):259-69. DOI: 10.1007/BF01310565
Source: PubMed

ABSTRACT Pigs vaccinated twice intramuscularly with a highly attenuated strain of vaccinia virus (NYVAC) containing gene inserts for pseudorabies virus (PRV) glycoproteins gp50, gII, and gIII produced neutralizing antibodies for PRV and were less clinically affected than were nonvaccinated pigs following oronasal exposure to virulent PRV. Also, following oronasal exposure to virulent PRV the duration of virulent virus shedding by pigs that had been vaccinated intramuscularly with the recombinant virus was statistically less (p < 0.05) than that of nonvaccinated pigs and like that of pigs vaccinated twice intramuscularly with inactivated PR vaccine. Intramuscular vaccination with the recombinant virus was compatible with the most commonly used differential diagnostic tests, namely those based on PRV glycoproteins gX and gI. Serum antibodies for these glycoproteins were absent from the sera of all pigs before and after vaccination with recombinant virus; whereas, they were present in the sera of all of the same pigs after they were exposed to virulent PRV. In contrast to the effectiveness of the recombinant virus administered intramuscularly, neither serum antibody nor clinical protection against PRV was detected when aliquots of the same recombinant virus preparation were administered either orally or intranasally. The latter finding suggests that recombinant virus replicates poorly, if at all, at these sites. If so, the dissemination of recombinant virus from vaccinated pigs to nonvaccinated pigs or other animals in contact seems unlikely.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The glycoprotein gB of pseudorabies virus (PrV) was expressed in various mammalian cells by a recombinant baculovirus carrying the PrV gB gene under the control of the CAG promoter. When the recombinant baculovirus was inoculated into the stable porcine kidney cell line CPK, expression of PrV gB was detected by immunofluorescent antibody analysis and a 155 kDa of protein, which has the same molecular mass as the native PrV gB, was detected by Western blotting. High levels of expression of PrV gB were observed in BHK-21, HmLu-1 and SK-H cell lines. Furthermore, anti-PrV gB-specific antibodies against PrV gB protein were detected by the enzyme-linked immunosorbent assay in mice inoculated the recombinant baculovirus. The recombinant baculovirus containing the PrV glycoprotein gB gene under the CAG promoter could be a candidate for a pseudorabies vaccine.
    Veterinary Microbiology 08/1999; 68:197-207. · 2.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study demonstrates the protective potential of novel baculovirus recombinants, which express the glycoproteins gB, gC, or gD of Pseudorabies virus (PRV; Alphaherpesvirus of swine) and additionally contain the glycoprotein G of Vesicular Stomatitis Virus (VSV-G) in the virion (Bac-G-PRV). To evaluate the protective capacity, mixtures of equal amounts of the PRV gB-, gC-, and gD-expressing baculoviruses were used for immunization. Three intramuscular immunizations with that Bac-G-PRV mixture could protect mice against a lethal PRV challenge infection. To achieve complete protection high titers of Bac-G-PRV and three immunizations were necessary. This immunization with Bac-G-PRV resulted in the induction of high titers of PRV-specific serum antibodies of the IgG2a subclass and of interferon (IFN)-gamma, indicating a Th1-type immune response. Moreover, splenocytes of immunized mice exhibited natural killer cell activity accompanied by the production of IFN-alpha and IFN-gamma. Collectively, the presented data demonstrate for the first time that co-expression of VSV-G in baculovirus recombinant vaccines can improve the induction of a protective immune response against foreign antigens.
    Vaccine 07/2009; 27(27):3584-91. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adenovirus and poxvirus recombinant vectors are more and more used as live experimental vaccines. In order to compare the efficacy of these vectors to elicit serological response and protection against challenge, two recombinants carrying the same gene (pseudorabies virus gD) were used as experimental vaccines in mice, a permissive species to pseudorabies infection. Two routes were tested: intramuscular (i.m.) and intranasal (i.n.) in order to try to stimulate general and mucosal immune responses. Several doses ranging from 10(2.9) to 10(8.9) TCID50, depending on the vaccines were tested. The estimated log 10 (PD50) for the i.m. route were 7.1 +/- 0.2 for the adenovirus vector (Ad-gD), and 7.6 +/- 0.2 for the Nyvac vector (vP900). For the i.n. route, log 10 (PD50) of Ad-gD was 7.1 +/- 0.2, and was higher than 7.9 for vP900. While the adenovirus vector proved more efficient than the poxviral vector to elicit antibody response, only a slight difference was observed when comparing the survival times of animals after challenge. Adenovirus was found better only for the 10(7.9) TCID50 dose, when inoculated i.m. Intranasal vaccination appeared efficient only with the adenovirus vector for the TCID50 10(8.9) dose.
    Vaccine 09/1996; 14(11):1083-7. · 3.49 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014